Get the Stockscreener App
33.93
2.25%
-0.78
After Hours:
34.45
0.52
+1.53%
Hims Hers Health Inc stock is traded at $33.93, with a volume of 20.56M.
It is down -2.25% in the last 24 hours and down -26.78% over the past month.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
See More
Previous Close:
$34.71
Open:
$36.15
24h Volume:
20.56M
Relative Volume:
1.07
Market Cap:
$7.54B
Revenue:
$1.24B
Net Income/Loss:
$101.26M
P/E Ratio:
77.11
EPS:
0.44
Net Cash Flow:
$149.62M
1W Performance:
-17.02%
1M Performance:
-26.78%
6M Performance:
+114.48%
1Y Performance:
+132.08%
1-Day Range:
$32.77
$37.28
1-Week Range:
$32.68
$38.69
52-Week Range:
$11.20
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Industry
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
33.93 | 7.54B | 1.24B | 101.26M | 149.62M | 0.44 |
|
PG
Procter Gamble Co
|
168.37 | 394.80B | 84.35B | 15.48B | 15.47B | 6.28 |
|
UL
Unilever Plc Adr
|
59.03 | 147.09B | 65.10B | 6.16B | 0 | 2.4569 |
|
CL
Colgate Palmolive Co
|
90.82 | 74.20B | 20.10B | 2.89B | 3.55B | 3.52 |
|
KMB
Kimberly Clark Corp
|
139.97 | 46.42B | 20.06B | 2.55B | 2.51B | 7.55 |
|
KVUE
Kenvue Inc
|
23.07 | 44.09B | 15.46B | 1.03B | 1.34B | 0.53 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers - Yahoo Finance
Hims & Hers threw a Super Bowl Hail Mary that landed incomplete. Now the receiver is on the sidelines. - Sherwood News
Check Out What Whales Are Doing With HIMS - Benzinga
Why Hims & Hers Health Stock Faces Challenges - TipRanks
Cautious Outlook on Hims & Hers Health Amid Aggressive Revenue Targets and Competitive Challenges in Weight Loss Market - TipRanks
Keybank National Association OH Takes $237,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS) - Defense World
Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Smartleaf Asset Management LLC - Defense World
Why the Market Dipped But Hims & Hers Health, Inc. (HIMS) Gained Today - Yahoo Finance
Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook - TipRanks
Why Hims & Hers Health Stock Just Popped - Yahoo
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
BofA reiterates Hims & Hers stock underperform rating - Investing.com
Should You Buy Hims & Hers Stock On The Dip? - Barchart
Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity? - The Globe and Mail
Hims & Hers Health Stock: A Millionaire-Maker in the Making? - AOL
Define Ventures Appoints Carolyn Magill as Venture Partner -March 11, 2025 at 05:31 am EDT - Marketscreener.com
Jones Financial Companies Lllp Raises Stake in Hims & Hers Health, Inc. (NYSE:HIMS) - Defense World
Bay Area startup, a few years after being bought for $131M, shuts down - SFGATE
Citi maintains sell on Hims & Hers stock, target at $27 - Investing.com
(HIMS) Proactive Strategies - Stock Traders Daily
Hims & Hers closed down Apostrophe, a skin care startup it bought four years ago - Sherwood News
3 Cold Stocks That Can Bounce Back This Week - The Motley Fool
Hims & Hers Health Discontinues Dermatology Business Apostrophe -March 10, 2025 at 07:30 am EDT - Marketscreener.com
28,961 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Mutual of America Capital Management LLC - Defense World
Bank of New York Mellon Corp Increases Holdings in Hims & Hers Health, Inc. (NYSE:HIMS) - Defense World
Hims & Hers Stock (HIMS) Soars on Plans to Shutter Acne Treatment Unit - TipRanks
Hims & Hers: AI-Powered Healthcare Disruption (NYSE:HIMS) - Seeking Alpha
Missed the Hims & Hers Rally? Clover Health Could Be Next - MSN
Hims & Hers to Discontinue Dermatology Line Apostrophe - Inc.
Is Hims & Hers Health, Inc. (HIMS) the Best Skincare Stock to Buy According to Hedge Funds? - Insider Monkey
Citigroup Reaffirms Sell Rating for Hims & Hers Health (NYSE:HIMS) - Defense World
Hims & Hers Health (NYSE:HIMS) Earns “Underperform” Rating from Bank of America - Defense World
Hims & Hers to shut down dermatology business Apostrophe - Reuters.com
Hims & Hers to Shut Down Dermatology Business Apostrophe - U.S News & World Report Money
Hims & Hers to shut down dermatology business Apostrophe -March 07, 2025 at 06:16 pm EST - Marketscreener.com
Hims & Hers abandons dermatology business Apostrophe it paid $190M for - Seeking Alpha
Hims And Hers Is Shutting Down Its Dermatology Business Apostrophe- Business Insider - Marketscreener.com
Hims and Hers bought a skincare startup for $190 million 4 years ago. Today they shut it down. - Yahoo Finance
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down. - Business Insider
Why Hims & Hers Health, Inc. (HIMS) Crashed on Thursday - Insider Monkey
Hims & Hers Tumbles on Discounted Wegovy - Money Morning
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade) - Seeking Alpha
Surprising decision sends weight-loss drug stock reeling - TheStreet
This Could Be a Huge Blow to Hims & Hers Health Stock - AOL
Hims & Hers Health Faces Competitive and Regulatory Challenges Amid Novo Nordisk’s New Offering and FDA Developments - TipRanks
Director Sells Major Stake in Hims & Hers Health! - TipRanks
Hims & Hers down as judge denies motion over end to Lilly’s Zepbound shortage - MSN
Hims & Hers' Weight-Loss Bet Hits a Wall--Is the Stock's $6 Billion Surge About to Unravel? - Yahoo Finance
Forecasting The Future: 15 Analyst Projections For Hims & Hers Health - Benzinga
Hims & Hers falls after a court ruling on a drug it never sold - Sherwood News
Why Hims & Hers Stock Just Collapsed - AOL
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):